[en] The aim of the study was to measure the results of a 15-year health promotion strategy towards osteoporosis, in an urban community of subjects over 45 years old, in terms of osteoporosis awareness and handling. To this end an ancillary study to a large survey of the Belgian population's self-perceived health status was carried out. A rectangular sample of 4800 individuals over 45 years old was randomly selected in two Belgian cities, among the affiliates of the two main health insurance providers. One of the cities (Liege) had been, since the early 1980s, the target of a constant health promotion strategy, directed to both the medical community and the general population, aimed at increasing osteoporosis awareness in women after the menopause. During the same period, no particular steps were taken in the other city (Aalst) to increase osteoporosis awareness in the community. In our study, the participants were asked to spontaneously report any chronic, serious and/or severe disorders that they had been suffering from, for at least 6 months, during the previous 12 months. They also provided a list of drugs they were taking at the time of the survey. Osteoporosis was reported to be a disease affecting 1.5% of men in Aalst and 1.3% of men in Liege (p = 0.61). For women, osteoporosis was reported to be present in 4.8% in Aalst and 10.8% in Liege (p<0.001). Self-reporting of osteoporosis prevalence in Liege was statistically significantly higher in women aged 45-64 years, 65-74 years or over 75 years (p<0.001). Obesity, alcohol consumption or physical activity were equally distributed between women from Liege and Aalst. Prescription drugs used for osteoporosis had been delivered to a similar proportion of men in Aalst and Liege. In women, a statistically significant difference in these prescription drugs was observed between Liege and Aalst, both for the overall population (p<0.001) and in each of the age classes (p<0.001 for 45-64 years and 65-74 years; p<0.009 for over 75 years). A continuous long-term health promotion strategy, directed toward both physicians and the general population, thus appears to increase awareness about osteoporosis in women over 45 years and/or in the medical community. This is reflected by an increase in self-reported prevalence of osteoporosis and in the prescription of drugs aimed at prevention and treatment of this disorder. Whether these observations reflect an appropriate diagnosis and a proper handling of the disease remains to be evaluated by objective diagnostic tools such as bone densitometry and by an evaluation of the effectiveness of prescription practices in postmenopausal women.
Disciplines :
Rheumatology
Author, co-author :
Tellier, V.
De Maeseneer, J.
De Prins, L.
Sedrine, W. B.
Gosset, Christiane ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique : aspects généraux
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Language :
English
Title :
Intensive and Prolonged Health Promotion Strategy May Increase Awareness of Osteoporosis among Postmenopausal Women
Keene G.S., Parker M.J., Pryor G.A. (1993) Mortality and morbidity after hip fractures. BMJ 307:1219-1250.
Chrischilles E., Shireman T., Wallace R. (1994) Costs and health effects of osteoporotic fractures. Bone 15:377-386.
Reginster J.-Y., Gillet T.P., Ben Sedrine W., Brands G., Ethgen O., De Froidmont C., Gosset C. (1999) Direct costs of hip fractures in patients over 60 years of age in Belgium. Pharmacoeconomics 15:507-514.
Melton L.J. (1993) Hip fractures: A worldwide problem today and tomorrow. Bone 14.
Gillet P., Reginster J.-Y. (1999) Increased number of hip fractures. Lancet 353:2160-2161.
Tosteson A., Rosenthal D., Melton J., Weinstein M. (1990) Cost effectiveness of screening perimenopausal white women for osteoporosis: Bone densitometry and hormone replacement therapy. Ann Intern Med 113:594-603.
Torgeson D.J., Reid D.M. (1997) The economics of osteoporosis and its prevention. Pharmacoeconomics 11:126-138.
(1998) Osteoporosis: Review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporos Int 8(SUPPL. 4).
Genant K., Cooper C., Poor G. (1999) Interim report and recommendations of the World Health Organization task-force for osteoporosis. Osteoporos Int 10:259-264.
Abbott T.A., Mucha L., Manfredonia D. (1999) Efficient patient identification strategies for women with osteoporosis. J Clin Densitom 2:223-230.
Siris E., Abbott T., Berger M. (1999) How well do primary care physicians follow the NOF recommendations? The NORA experience. J Bone Miner Res 14(SUPPL. 1).
Torgerson D.J., Dolan P. (1998) Prescribing by general practitioners after an osteoporotic fracture. Ann Rheum Dis 57:378-379.
Lamberts H., Wood M. ICPC international classification of primary care, Oxford: Oxford University Press WONCA; 1987.
Magnus J.H., Joakimsen R.M., Tollan A., Stogaard A.J. (1996) What do Norwegian women and men know about osteoporosis?. Osteoporos Int 6:32-36.
Phillipov G., Phillips P.J., Leach G., Taylor A.W. (1998) Public perceptions and self-reported prevalence of osteoporosis in South Australia. Osteoporos Int 8:552-556.
Looker A.C., Orwoll E.S., Johnston C.C. (1997) Prevalence of low femoral bone density in older US adults from NHANES III. J Bone Miner Res 12:1761-1768.
(1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843, Geneva: WHO; .
Reginster J.Y. (1996) Harmonization of clinical practice guidelines for the prevention and treatment of osteoporosis and osteopenia in Europe: A difficult challenge. Calcif Tissue Int 59(SUPPL. 1):24-29.
Rozenberg S., Kroll M., Vandromme J. (1997) Factors influencing the prescription of hormone replacement therapy. Obstet Gynecol 90:387-391.
Rozenberg S., Vandromme J., Kroll M. (1994) Osteoporosis prevention with sex hormone replacement therapy. Int J Fertil 39:262-271.
Ryan P.J., Harrison R., Blake G.M., Fogelman I. (1992) Compliance with hormone replacement therapy (HRT) after screening for postmenopausal osteoporosis. Brit J Obstet Gynaecol 99:325-328.
Groeneveld F., Bareman F., Bzrentsen R. (1998) Duration of hormonal replacement therapy in general practice; a follow-up study. Maturitas 29:125-131.